BridgeMD
New treatment option for Breast Neoplasms
Official title Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors
ClinicalTrials.gov ID: NCT07465393
What this study is testing
- What it's testing
- This study evaluates the comparative effectiveness of a multi-modal facility-based rehabilitation program (therapist-led resistance exercise and relaxation training) versus a self-directed home-based resistance exercise program in post-treatment breast cancer survivors. Participants in both intervention groups will complete a 16-week program consisting of two exercise sessions per week.The multimodal, therapist-led approach is hypothesized to result in superior improvements in physical performance and quality of life outcomes compared to self-directed home exercise
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- Histologically confirmed primary breast cancer
- Stage I-III non-metastatic breast cancer following lumpectomy or mastectomy
- Completed adjuvant chemotherapy (with or without radiotherapy)
- Age ≥ 18 years
- Able to understand and follow the study protocol
You likely can't join if
- Metastatic (Stage IV) breast cancer
- Morbid obesity (BMI \> 40 kg/m²)
- Uncontrolled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 99 mmHg)
- Presence of implantable medical devices (e.g., pacemakers, nerve stimulators)
- Presence of metallic surgical implants (e.g., total hip or knee replacements) that interfere with assessment devices
- Contraindications for resistance training (e.g., acute infectious disease, severe cardiac disease, severe respiratory insufficiency)
See the full eligibility criteria
- Histologically confirmed primary breast cancer
- Stage I-III non-metastatic breast cancer following lumpectomy or mastectomy
- Completed adjuvant chemotherapy (with or without radiotherapy)
- Age ≥ 18 years
- Able to understand and follow the study protocol
- Willingness to attend facility-based exercise training.
- Metastatic (Stage IV) breast cancer
- Morbid obesity (BMI \> 40 kg/m²)
- Uncontrolled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 99 mmHg)
- Presence of implantable medical devices (e.g., pacemakers, nerve stimulators)
- Presence of metallic surgical implants (e.g., total hip or knee replacements) that interfere with assessment devices
- Contraindications for resistance training (e.g., acute infectious disease, severe cardiac disease, severe respiratory insufficiency)
- Concurrent malignant diseases
- Current participation in intense systematic exercise training (defined as at least 1 hour, twice per week)
- Previous participation in an exercise intervention clinical trial.
The study team makes the final eligibility decision.
Where it's taking place
- New Taipei City, Xindian Dist, Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New Taipei City, Xindian Dist, Taiwan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.